US EditionPublished • loading... • Updated
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
Summary by Laotian Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson’s Disease and Movement Disorders® 20251-3 MSA is a rare, rapidly progressing, neurodegenerative disease with no approved treatments available4,5 The innovative design of the pivotal MASCOT trial aims […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
